Literature DB >> 22392186

Obesity, inflammation and brachial artery flow-mediated dilatation: therapeutic targets in patients with microvascular angina (cardiac syndrome X).

Peter Ong1, Ramyya Sivanathan, Gabor Borgulya, Mukhtar Bizrah, Yassir Iqbal, Joycelyn Andoh, David Gaze, Juan Carlos Kaski.   

Abstract

BACKGROUND: The pathophysiology of microvascular angina (cardiac syndrome X, CSX), (effort-induced angina, a positive response to exercise stress testing and angiographically normal coronary arteries) has not been fully elucidated. Various pathogenic mechanisms have been proposed, amongst which coronary microvascular dysfunction features prominently. Management of patients with microvascular angina is often challenging as a substantial number of patients does not respond to conventional anti-anginal therapy. In this study, we sought to assess the association between brachial artery FMD, high-sensitive C-reactive protein (hs-CRP) and cardiovascular risk factors including obesity in patients with cardiac syndrome X. METHODS AND
RESULTS: Thirty-four consecutive CSX patients (29 female, mean age 60 ± 9 years) were recruited from a specialised CSX clinic. Twelve asymptomatic subjects (10 female, mean age 51 ± 12 years) with comparable cardiovascular risk factor profile served as controls. All participants underwent standardized computer-assisted FMD measurements and assessment of hs-CRP concentrations at study entry. Body mass index (BMI), used as a general measure of obesity was calculated as weight (kilograms) divided by height (meters squared). Compared to controls, CSX patients had significantly higher hs-CRP concentrations (p = 0.003) and impaired FMD (p < 0.01). Moreover, among the CSX patients, a correlation between FMD and hs-CRP (r = -0.66, p < 0.01), FMD and BMI (r = 0.377, p = 0.028), and hs-CRP and BMI (r = -0.372, p = 0.030) was found.
CONCLUSION: Impaired brachial artery FMD is significantly associated with elevated hs-CRP concentrations and BMI in patients with CSX. The results support the concept that low-grade inflammation and obesity may promote vascular dysfunction in these patients representing therapeutic targets for future research investigations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392186     DOI: 10.1007/s10557-012-6382-4

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  7 in total

1.  Remarkable points for cardiovascular studies in fibromyalgia syndrome management.

Authors:  Selçuk Sayılır
Journal:  Clin Rheumatol       Date:  2016-05-19       Impact factor: 2.980

Review 2.  Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.

Authors:  C Noel Bairey Merz; Carl J Pepine; Mary Norine Walsh; Jerome L Fleg
Journal:  Circulation       Date:  2017-03-14       Impact factor: 29.690

3.  Current Diagnostic and Therapeutic Strategies in Microvascular Angina.

Authors:  Bryn Mumma; Nathalie Flacke
Journal:  Curr Emerg Hosp Med Rep       Date:  2015-03

4.  Association of Inflammation and Endothelial Dysfunction with Coronary Microvascular Resistance in Patients with Cardiac Syndrome X.

Authors:  Ming Long; Zhibin Huang; Xiaodong Zhuang; Zena Huang; Yue Guo; Xinxue Liao; Chufan Luo
Journal:  Arq Bras Cardiol       Date:  2017-10-19       Impact factor: 2.000

5.  Right ventricular-pulmonary arterial coupling impairment and exercise capacity in obese adults.

Authors:  Na Zhou; Kevin Forton; Yoshiki Motoji; Corentin Scoubeau; Malgorzata Klass; Robert Naeije; Vitalie Faoro
Journal:  Front Cardiovasc Med       Date:  2022-08-19

Review 6.  Obesity Related Coronary Microvascular Dysfunction: From Basic to Clinical Practice.

Authors:  K Selthofer-Relatić; I Bošnjak; A Kibel
Journal:  Cardiol Res Pract       Date:  2016-03-22       Impact factor: 1.866

7.  Evaluation of the coronary flow by the coronary clearance time in patients with cardiac syndrome X.

Authors:  Erkan Yildirim; Uygar Cagdas Yuksel; Murat Celik; Baris Bugan; Mutlu Gungor; Yalcin Gokoglan; Mustafa Koklu; Suat Gormel; Salim Yasar; Cem Barcin
Journal:  J Int Med Res       Date:  2017-12-04       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.